Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Do docetaxel nanoparticles boost response in mCRPC?

Autio KA et al. JAMA Oncol. 2018 July 5. doi: 10.1001/jamaoncol.2018.2168.

Key clinical point: A docetaxel-encapsulating nanoparticle targeted against prostate-specific membrane antigen (PSMA) was safe and showed good activity in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) .

Major finding: The 6-month progression-free survival rate, the primary endpoint, was 65%.

Study details: Open-label, phase 2 trial of 42 men with mCRPC that progressed on abiraterone acetate and/or enzalutamide.

Disclosures: The study was funded by BIND Therapeutics and by grants from the National Institutes of Health, Sidney Kimmel Center for Prostate and Urologic Cancers, and the David H. Koch Prostate Cancer Research Fund. Dr. Autio had no disclosures. Several coauthors are employees of BIND Therapeutics, and others are employed by Epic Sciences, maker of the CTC assay used in the study. Other coauthors reported advising/consulting, research support, and speakers bureau activities for multiple companies.

Source: Autio KA et al. JAMA Oncol. 2018 July 5. doi: 10.1001/jamaoncol.2018.2168.

Read the article.

Citation:

Autio KA et al. JAMA Oncol. 2018 July 5. doi: 10.1001/jamaoncol.2018.2168.

This Week's Must Reads

Perioperative radiation therapy underused in elderly patients with soft tissue sarcomas, Venigalla S et al. Intl J Rad Oncology*Biology*Physics; September (102) 2018: 155-165. https://doi.org/10.1016/j.ijrobp.2018.05.019

Age, R0 resection, and adjuvant radiotherapy boost outcomes in myxofibrosarcoma, Boughzala-Bennadji R et al. Intl J Rad Oncology*Biology*Physics; October (102) 2018: 399-406. https://doi.org/10.1016/j.ijrobp.2018.05.055

Tumor size, invasion beyond subcutaneous fat predict adverse outcomes in undifferentiated pleomorphic sarcoma, Winchester D et al. J Am Acad Dermatol. Available online 19 May 2018 https://doi.org/10.1016/j.jaad.2018.05.022

High recurrence rate after pancreaticoduodenectomy for primary retroperitoneal sarcoma, Tseng W et al. European Journal of Surgical Oncology 2018 (44): June; 810-815.

Nivolumab, pembrolizumab successfully used in Kaposi sarcoma, Galanina et al. Cancer Immunol Res. 2018 Sept 7. doi: 10.1158/2326-6066.CIR-18-0121.

Must Reads in Genitourinary Cancer

Leptin expression may aid in differentiation of renal lesions, Gobe G et al. Pathology. 2018 Aug;50(5):504-10

Hypofractionated radiation offers 'tailored treatment' approach to RCC mets, Felice F et al. Crit Rev Oncol Hematol. 2018 Aug 1. doi: 10.1016/j.critrevonc.2018.06.002.

Concern over SREs rises with increasing incidence of metastatic RCC, Umer M et al. Ann Med Surg. 2018 Jan 21. doi: 10.1016/j.amsu.2018.01.002

Radioactive agent approved for adrenal tumors, FDA approves iobenguane I 131 injection (Azedra) for IV use for the treatment of pheochromocytoma or paraganglioma. 

Estimated conditional OS shows upfront TKI benefit in mRCC, Kang M et al. J Urol. 2018 June 22. doi: 10.1016/j.juro.2018.06.030